MUMBAI (NewsRise) -- Lupin is tying up a string of licensing deals with global pharmaceutical companies as the Indian drugmaker seeks to boost revenue and pare costs amid regulatory issues and a slow pace of pick up in new launches in the U.S.
Pharmaceuticals
Lupin seeks to pare new drug costs with string of licensing deals
Indian pharmaceutical firm seeks to control expenses amid slow US business